We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Three House Democrat committee chairs are demanding that HHS Secretary Alex Azar detail how the department is gearing up for COVID-19 vaccine distribution, how it is working to increase public faith in a vaccine and how it will ensure its decisions aren’t influenced by politics. Read More
Sanofi’s chief in France, Olivier Bogillot, announced Tuesday that shots of the company’s COVID-19 vaccine candidate would likely cost below $11.80 (10 Euro) in Europe should it be approved, in the mid-range of prices that drugmakers are disclosing. Read More
President Trump’s efforts to coax a new strategy from industry to lower drug prices by means of a brandished executive order have been met with silence so far, and the administration is running out of time to show some headway on drug pricing before the Nov. 3 presidential election. Read More
AstraZeneca has paused a late-stage trial of its promising COVID-19 vaccine candidate while it evaluates a single UK patient who may have experienced a serious adverse reaction. Read More
After returning from a month-long congressional hiatus, Senate Majority Leader Mitch McConnell (R-Ky) unveiled a proposed coronavirus relief package on Tuesday that includes $31 billion for COVID-19 medical countermeasures. Read More
In prepared remarks at a Senate hearing today, National Institutes of Health Director Francis Collins is expected to say that there is “growing optimism” that one of the multiple COVID-19 vaccine candidates will prove safe and effective by late 2020 or early 2021. Read More
The FDA cited Fresenius Kabi following an inspection of its Melrose Park, Illinois plant that revealed multiple deficiencies, including a failure to properly deal with product contamination. Read More
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has called for revoking the marketing authorizations of Esmya (ulipristal acetate) and its generics for uterine fibrosis after confirming the drug can cause serious liver injuries. Read More
Multiple drugmakers have reportedly drafted a public pledge not to seek FDA approval of their COVID-19 vaccines until they meet certain safety and efficacy standards even as President Trump said a vaccine may be ready as soon as October. Read More